Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$22.00
-HK$0.68(-3.17%)
At close: 4:00 PM EDT
HK$22.00
-HK$0.68(-3.17%)
Day’s Range― - ―
52-Week RangeHK$19.48 - HK$35.34
Previous CloseN/A
Volume2.14M
Average Volume (3M)5.91M
Market Cap
HK$23.78B
Enterprise ValueHK$24.84K
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 31, 2027EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.87Price Target Upside81.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$1.18B
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe sharp acceleration indicates improving commercial traction for the company’s robotic systems and related products. Sustained growth could expand the installed base and create a larger foundation for recurring instruments, consumables, and service revenue.
Positive Gross MarginA positive gross margin shows that products generate economic contribution before operating expenses, while improving losses suggests progress toward better operating leverage. Further scale could support profitability, although sustainability remains unproven.
Improved LeverageThe substantial reduction in leverage lowers balance-sheet pressure and may improve financial flexibility as the company commercializes its medical robotics portfolio. It provides a stronger capital structure than the prior year, despite ongoing equity risks.
Bears Say
Persistent Net LossesThe company has not demonstrated sustainable operating profitability despite strong revenue growth. Continued losses can require additional funding, limit reinvestment flexibility, and weaken the ability to absorb commercialization costs or slower hospital adoption.
Negative Cash GenerationRepeated negative operating and free cash flow means the business is not yet self-funding its expansion. Ongoing cash burn may increase reliance on external financing and constrain investment in product development, manufacturing capacity, and commercialization.
Severe Negative ReturnsDeeply negative returns indicate that the capital base is not currently producing shareholder value and remains under pressure from accumulated losses. Continued equity erosion could weaken financial resilience even though leverage improved during 2025.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$19.48 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$23.78B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 214 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Aug 27, 2026. The company reported HK$0.035 earnings per share for the quarter, the consensus estimate of HK$0.035 by HK$0.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of HK$0.035 in its last earnings report, expectations of HK$0.035. Following the earnings report the stock price went up 2.596%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$39.87 (81.21% Upside)
HK$39.87 (81.21% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$39.87
▲(81.21% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―